bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2013: M A M F J
2012: D N O S A J J M

 
  Other news for:
Breast Neoplasms
Neoplasms
 Resources from HONselect
Least Aggressive Breast Cancer Still Poses Long-Term Risk, Study Finds
Women with common tumor types might die of disease a decade later, affecting treatment decisions

By Robert Preidt

TUESDAY, Sept. 18 (HealthDay News) -- The most common and least aggressive form of breast cancer still poses a risk of death more than 10 years after a woman is diagnosed with the disease, according to a new long-term study.

The findings could affect how doctors treat women with this type of breast cancer, the researchers said.

Their 21-year study of nearly 1,000 women in California found that molecular subtypes of breast cancer were important independent predictors of death from breast cancer. In particular, women with luminal A tumors (a subtype of breast cancer generally believed to have the best prognosis) were still at risk for death from the cancer more than 10 years after their diagnosis.

The researchers at Kaiser Permanente Southern California also found that women with HER2-enriched and luminal B tumors were about twice as likely to die from breast cancer than those with luminal A tumors. That result is consistent with previous research.

"The findings of this study indicate that it is important to consider breast cancer molecular subtypes in determining the optimal treatment for women with breast cancer," study author Reina Haque said in a Kaiser news release. "Women with luminal A tumors -- the least aggressive but most common cancerous breast tumor -- could benefit from extended treatment to improve their chances for long-term survival."

The study appeared Sept. 18 in the journal Cancer Epidemiology, Biomarkers & Prevention.

Breast cancer tumors often are divided into four molecular subtypes, the researchers explained in the news release:

  • Luminal A, which tends to have the best prognosis with fairly high survival rates.
  • Luminal B, which typically occurs in younger women and has a poor prognosis.
  • Basal-like subtype, which also tends to occur in younger women, as well as in black women, and has a poor prognosis.
  • HER2-enriched subtype, which has a fairly poor prognosis and is prone to early and frequent recurrence and metastases (the spread of the disease to other parts of the body).

Of the four subtypes, luminal A accounts for between 42 percent and 59 percent of all breast cancer cases, the release noted.

"These and earlier findings strongly support molecular subtypes as important independent predictors of breast cancer mortality," Haque said. "It is important for women with breast cancer -- even those diagnosed with the least aggressive form of the disease -- to be an advocate for their own health and speak to their doctors about treatment options."

More information

The American Cancer Society has more about breast cancer.

SOURCE: Kaiser Permanente, news release, Sept. 18, 2012

Copyright © 2012 HealthDay. All rights reserved. URL:http://www.healthscout.com/template.asp?id=668730

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Breast
Breast Neoplasms
Women
Risk
Phenobarbital
Prognosis
Therapeutics
Research Personnel
Death
Affect
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact